Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,503 active trials44 approved drugs144 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,923 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (759)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03473925 | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | completed | Phase 2 | 107 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 28, 2024 | clinicaltrials |
| NCT05783167 | Self-collected Vaginal and Urine Samples in HIV-positive Women | completed | — | 502 | University of AarhusOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT01606241 | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT01344837 | Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer | completed | — | 360 | Gynecologic Oncology GroupNETWORK | 1 | Aug 14, 2024 | clinicaltrials |
| NCT03539406 | Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients(INTRO) | completed | Phase 1 | 11 | Radboud University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05112627 | Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy | completed | — | 15 | Mayo ClinicOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT02773849 | ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 157 | Ferring PharmaceuticalsINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03602586 | Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2024 | clinicaltrials |
| NCT06517433 | First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 62 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06517485 | First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 142 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT02501954 | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | completed | Phase 3 | 48 | Women's Cancer Care Associates, LLCOTHER | 2 | Jul 23, 2024 | clinicaltrials |
| NCT02344095 | A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer(POPOPO) | completed | Phase 1 | 12 | Seoul National University HospitalOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT04257045 | Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives | completed | — | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03200587 | Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) | completed | Phase 1 | 12 | University of UtahOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03502330 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | completed | Phase 1 | 42 | Yale UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03557918 | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | completed | Phase 2 | 26 | Matthew GalskyOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03829111 | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | completed | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06483399 | Research on Nutritional Risk Indexes and Inflammatory Indicators in Postoperative Complications and Prognosis of Epithelial Ovarian Cancer Patients | completed | — | 1,108 | Qinglei GaoOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT00026663 | Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance | completed | — | 86 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2024 | clinicaltrials |
| NCT02408406 | PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers | completed | N/A | 140 | City of Hope Medical CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT02808143 | Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer | completed | Phase 1 | 9 | Northwestern UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03220945 | Comprehensive Yoga Program (SKY) as Adjunct Therapy for Prostate Cancer | completed | N/A | 45 | Emory UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04408924 | Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer(CYCLONE 1) | completed | Phase 2 | 44 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 25, 2024 | clinicaltrials |
| NCT04284761 | A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer(Biolen-PC) | completed | Phase 1 | 17 | Alessa Therapeutics Inc.INDUSTRY | 3 | Jun 24, 2024 | clinicaltrials |
| NCT01002937 | Novel Prognostic Markers in Renal Cancer | completed | — | 182 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04518046 | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | completed | Phase 1 | 22 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jun 5, 2024 | clinicaltrials |
| NCT03776123 | Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients | completed | — | 347 | IpsenINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT02184533 | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | 15 | Stanford UniversityOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT02830165 | Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery | completed | N/A | 11 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT04593381 | Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer(MITO-RT3/RAD) | completed | N/A | 376 | Gemelli Molise HospitalOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT02164461 | Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer | completed | Phase 1 | 12 | Advaxis, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study(89ZR-TLX250) | completed | Phase 3 | 300 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 8 | May 17, 2024 | clinicaltrials |
| NCT03093155 | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab | completed | Phase 2 | 78 | Yale UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT02163317 | Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer | completed | N/A | 12 | Case Comprehensive Cancer CenterOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT02668913 | LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer | completed | N/A | 72 | Geoff HallOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05127850 | MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer | completed | N/A | 51 | University of California, San FranciscoOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib(CATCH-R) | completed | Phase 3 | 34 | pharmaand GmbHINDUSTRY | 6 | May 7, 2024 | clinicaltrials |
| NCT04972682 | [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer(SENTRY) | completed | N/A | 102 | Moscow City Oncology Hospital No. 62OTHER_GOV | 1 | May 7, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Aug 28, 2024source: clinicaltrials